{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053963","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.067291+00:00","generated_at":"2026-06-02T21:23:36.783647+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Heron Q1 2024 net product sales $34.7M (+17% YoY); net loss per share improves to $(0.02)","bullets":["Net product sales $34.7M vs $29.6M YoY; net loss per share $(0.02) vs $(0.27).","Gross margin improved to 76% in Q1 2024 from 43% in Q1 2023.","ZYNRELEF net sales $5.0M (+43% YoY); FDA expanded indication approved Jan 23, 2024, covering soft tissue and orthopedic procedures.","Reaffirmed FY2024 guidance: product revenues $138-158M, adjusted operating expenses $108-116M, adjusted EBITDA $(22)-$3M.","Partnership with CrossLink Life Sciences; 191 CrossLink sales reps trained and engaged with physicians."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053963","json":"https://secwatch.observer/filing/0000950170-24-053963.json","markdown":"https://secwatch.observer/filing/0000950170-24-053963.md","text":"https://secwatch.observer/filing/0000950170-24-053963.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017024053963/0000950170-24-053963-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017024053963/hrtx-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:23:36.783647+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a9fcdda7780b7cddf4a193f84a95942b361a8ed9","claim":"HERON THERAPEUTICS, INC. /DE/ reported three months ended March 31, 2024 results: revenue Net Product Sales of $34.7 million, EPS Net Loss Per Share $(0.02). Guidance reaffirmed.","evidence_excerpt":"Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates • Net Product Sales of $34.7 million, which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02), which decreased from $(0.27) for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000095017024053963/0000950170-24-053963-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2024"},{"label":"Revenue","value":"Net Product Sales of $34.7 million"},{"label":"EPS","value":"Net Loss Per Share $(0.02)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}